cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Rain Therapeutics Inc
3 own
5 watching
Current Price
$10.02
$0.02
(0.2%)
logo-rain
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
266.18M
52-Week High
52-Week High
14.48
52-Week Low
52-Week Low
2.15
Average Volume
Average Volume
0.31M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization266.18M
icon52-Week High14.48
icon52-Week Low2.15
iconAverage Volume0.31M
iconDividend Yield--
iconP/E Ratio--
What does the Rain Therapeutics Inc do?
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
Read More
How much money does Rain Therapeutics Inc make?
News & Events about Rain Therapeutics Inc.
Globe Newswire
5days ago
Intermittent dosing of milademetan, an inhibitor of the p53-MDM2 complex, potentially exhibits an avenue to address historical issues with cytopenias with this class of compounds Phase 1 data in advanced dedifferentiated liposarcoma provides foundation for the registrational Phase 3 MANTRA trial ...
Globe Newswire
30days ago
NEWARK, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (Rain) (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that ...
Globe Newswire
1month ago
NEWARK, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53...
Globe Newswire
2 months ago
NEWARK, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53...
Globe Newswire
2 months ago
NEWARK, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53...
Frequently Asked Questions
Frequently Asked Questions
What is Rain Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Rain Therapeutics Inc shares?
plus_minus_icon
How can I buy Rain Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Rain Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Rain Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Rain Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Rain Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Rain Therapeutics Inc?
plus_minus_icon
What percentage is Rain Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Rain Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$10.02
$0.02
(0.2%)
logo-rain
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00